ST

Shawn Titcomb

CEO of the Allele companies (Allele Capital, Allele Ventures, and Allele Communications) / Co-Founder and Executive Chairman of Majesty Therapeutics / Board Member of Praesidia Biotherapeutics

Fort Lauderdale, Florida

Invests in

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Education

Work Experience

  • Co-Founder and Executive Chairman

    2024

    Majesty Therapeutics is a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics and companion diagnostics for the treatment of immune-mediated diseases.

  • Co-Founder and CEO

    2017

    Allele Capital is a merchant bank and strategic advisory firm that provides venture capital and private equity financing to private and small-cap public life sciences companies. Allele works in partnership with its clients to provide a suite of value-added services which include strategic advisory, proprietary capital, and non-proprietary capital through its executing investment bank, Wilmington Capital Securities, LLC a registered Broker-Dealer, Member FINRA and SIPC. All business executed through Wilmington is subject to FINRA and SEC rules and regulations. Whether through advisory or capital raising activities, Allele leverages its extensive proprietary network of advisors, C-Suite level management relationships and key opinion leaders (KOLs) for the benefit of its corporate and investment partners. Allele's principals' comprehensive experience in private-to-public and public venture process for small life sciences companies has resulted in significant shareholder equity and valuations of over $2 billion. www.allelecapital.com

  • Co-Founder and CEO

    2022

    Allele Communications is a fully-integrated communications firm that provides effective and impactful public relations, social and digital media, and traditional media solutions for companies in the life sciences and medical device industries. www.allelecommunications.com

  • Member Board Of Directors

    2021

    Praesidia is developing drugs with an increased therapeutic window through proprietary organ and cell-specific delivery, especially across the blood-brain barrier.

  • Head of Investment and Merchant Banking, Noble Life Science Partners

    2006 - 2017

    Noble Life Science Partners, a division of Noble Financial Capital Markets, is focused on investment banking, merchant banking and capital markets support for companies in the biotechnology, specialty pharmaceuticals and medical technology industries.

2003 - 2006

  • Founding Partner

    2003 - 2006

    Founding Partner and Director of independent equity research and trading boutique focused exclusively on U.S. based companies in the Biotechnology, Medical Technology and Specialty Pharmaceutical industries.

  • Sr. Vice President, Institutional Research Sales

    2000 - 2003

    Highest grossing institutional salesperson at firm focused exclusively on short biased research and trading in the healthcare industry.